AzTrials
AzTrials

Decompensated Heart FailureNCT07506499

Cardiac Rehabilitation in Decompensated Heart Failure

A study testing Inspiratory Muscle Trainer, Functional Electrical Stimulation and Standard medical treatment in people with Decompensated Heart Failure, run by Beni-Suef University at 1 site in Egypt.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Heart failure is a common clinical condition that often leads to reduced exercise tolerance, shortness of breath, and poor quality of life. Many patients with heart failure also develop weakness of the inspiratory muscles, which contributes to limited physical activity and worsening functional capacity. Read more about this study

Who is it for?
Ages 45 to 65 years
Conditions the study is for
Decompensated Heart Failure
What is being tested?
Inspiratory Muscle Trainer, Functional Electrical Stimulation and Standard medical treatment
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
135 participants
Where
1 siteEgypt
Study dates
1 Apr 2026to 1 Sep 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Aged from 45 to 65 years old
  • Both sexes
  • Hospitalized heart failure patients with ejection fraction < 40%
  • Conscious and cooperative
  • Able to participate in training actively

Who cannot join

  • Acute major cardiovascular events (e.g., acute coronary syndrome, stroke, or pulmonary embolism)
  • Uncontrolled life-threatening arrhythmias
  • Severe valvular heart disease requiring urgent surgery
  • Pregnancy
  • End-stage renal disease requiring dialysis
  • Significant pulmonary diseases such as pulmonary arterial hypertension,
Show all 10Show fewer
  • Implanted pacemaker
  • Clinically significant peripheral vascular disease
  • Severe anemia
  • Exercise-induced angina or ST-segment changes

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Salma mostafa Elsalhy, BSc contact

+20 1022792745

salmaabdelfattah@pt.bsu.edu.eg

MAHMOUD IBRAHIM MOHAMED, PT, PhD contact

+20 1142998414

Mahmoud.ibrahim@pt.bsu.edu.eg

Egypt1 site, 1 recruiting
  • Beni-Suef University Hospital

    Banī Suwayf, Beni-Suef Governorate

    Recruiting

Other trials in Egypt

About this study

Official title: Effect of Cardiac Rehabilitation in Patients With Decompensated Heart Failure

Heart failure is a common clinical condition that often leads to reduced exercise tolerance, shortness of breath, and poor quality of life. Many patients with heart failure also develop weakness of the inspiratory muscles, which contributes to limited physical activity and worsening functional capacity. Inspiratory muscle training (IMT) has been suggested as a useful rehabilitation method to improve respiratory muscle strength and exercise tolerance. In addition, functional electrical stimulation (FES) of the lower limb muscles may help activate skeletal muscles and improve functional performance in patients who cannot tolerate conventional exercise.

This randomized controlled study aims to investigate the effect of combining inspiratory muscle training with functional electrical stimulation of the lower limbs in patients with decompensated heart failure. A total of 135 hospitalized patients with decompensated heart failure will be recruited from the Cardiology Department at Beni-Suef University Hospital and randomly assigned into three groups. Group A (45 patients) will receive routine medical treatment in addition to inspiratory muscle training combined with functional electrical stimulation. Group B (45 patients) will receive routine medical treatment with inspiratory muscle training only. Group C (45 patients) will receive routine medical treatment alone.

The intervention will start during hospitalization and will continue for four weeks. The study will evaluate the effects of these interventions on cardiac function, inspiratory muscle strength, and functional capacity as primary outcomes. Secondary outcomes will include dyspnea severity, quality of life, heart rate, oxygen saturation, hand grip strength, and maximum expiratory pressure. The findings of this study may help clarify the potential role of combining inspiratory muscle training with functional electrical stimulation as part of cardiac rehabilitation in patients with decompensated heart failure.

Read the detailed description

Heart failure is a progressive clinical syndrome in which the heart is unable to maintain adequate cardiac output to meet the body's metabolic demands. Decompensated heart failure represents an acute or subacute deterioration requiring hospitalization and is associated with significant morbidity, prolonged hospital stays, and high readmission rates. Beyond the primary cardiac impairment, patients with decompensated heart failure commonly develop secondary systemic consequences, including respiratory muscle dysfunction and peripheral skeletal muscle abnormalities, both of which contribute independently to exercise intolerance, symptom burden, and poor functional outcomes.

Inspiratory muscle weakness has been identified in approximately 30-50% of patients with heart failure and is believed to result from a combination of diaphragmatic underperfusion, chronic hyperventilation, and systemic inflammatory and catabolic processes. This weakness leads to increased work of breathing, ventilatory inefficiency, and heightened perception of dyspnea, creating a vicious cycle that further limits physical activity and accelerates functional decline. Inspiratory muscle training (IMT) targets this mechanism by applying progressive resistive loading to the inspiratory muscles, promoting improvements in diaphragmatic strength, ventilatory efficiency, and autonomic modulation. Several studies have demonstrated favorable effects of IMT on inspiratory muscle performance, exercise capacity, and quality of life in stable heart failure populations; however, evidence regarding its application during the acute decompensated phase remains limited.

Peripheral skeletal muscle dysfunction in heart failure is characterized by a shift from type I oxidative to type II glycolytic muscle fibers, reduced mitochondrial density, impaired oxygen utilization, and muscle atrophy driven by disuse, neurohormonal activation, and systemic inflammation. These changes are particularly pronounced during periods of decompensation and prolonged bed rest. Functional electrical stimulation (FES) offers a passive approach to muscle activation that bypasses the cardiovascular demand of voluntary exercise, making it a potentially suitable intervention for hemodynamically unstable or severely deconditioned patients. FES-induced muscle contractions have been shown to improve local blood flow, enhance oxidative enzyme activity, and promote favorable fiber-type remodeling in heart failure populations.

Despite the established individual benefits of IMT and FES, no study to date has investigated the combined application of these two modalities in patients hospitalized with decompensated heart failure. The physiological rationale for combining them is based on the concept of addressing both central (respiratory muscle) and peripheral (skeletal muscle) components of exercise intolerance simultaneously, which may produce additive or synergistic improvements in functional capacity and clinical outcomes compared to either intervention alone.

This study hypothesizes that the addition of combined IMT and FES to routine medical treatment will result in greater improvements in cardiac function, inspiratory muscle strength, and functional capacity compared to IMT alone or medical treatment alone in patients with decompensated heart failure. The findings may contribute to the development of early, comprehensive cardiac rehabilitation strategies for this high-risk population.

Being tested
Inspiratory Muscle Trainer, Functional Electrical Stimulation, Standard medical treatment

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Inspiratory Muscle TrainerDevice

    Inspiratory muscle training performed using a threshold inspiratory muscle trainer at 30% of maximal inspiratory pressure for 30 minutes per session, 4-5 sessions per week for four weeks.

  • Functional Electrical StimulationDevice

    Functional electrical stimulation will be applied to the quadriceps and gastrocnemius muscles of both lower limbs using surface electrodes. Electrical stimulation will be delivered at a frequency of 10 Hz, pulse width of 150 ms, and 20 seconds on / 20 seconds off duty cycle for approximately 45 minutes per session.

  • Standard medical treatmentOther

    Participants will receive routine pharmacological treatment for heart failure according to hospital guidelines.

Study groups in NCT07506499
Study groupRoleWhat they receive
IMT + FES GroupExperimentalParticipants receive routine medical treatment combined with inspiratory muscle training and functional electrical stimulation of the lower limb muscles as part of a cardiac rehabilitation program.
Receives: Device: Inspiratory Muscle Trainer; Device: Functional Electrical Stimulation; Other: Standard medical treatment
IMT GroupActive comparatorParticipants receive routine medical treatment combined with inspiratory muscle training.
Receives: Device: Inspiratory Muscle Trainer; Other: Standard medical treatment
Control GroupActive comparatorParticipants receive routine medical treatment only.
Receives: Other: Standard medical treatment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Maximum Inspiratory Pressure

    Inspiratory muscle strength will be assessed by measuring maximum inspiratory pressure (MIP) using a maximum inspiratory pressure meter.

    Measured: Baseline and 4 weeks

Secondary outcomes (9)
  1. Dyspnea Severity

    Dyspnea severity will be assessed using the Modified Medical Research Council Dyspnea Scale (mMRC), which grades the impact of breathlessness on daily activities on a scale from 0 (minimum) to 4 (maximum), where higher scores indicate worse dyspnea severity.

    Measured: Baseline and 4 weeks

  2. Quality of Life (Minnesota Living with Heart Failure Questionnaire Score)

    Quality of life will be evaluated using the Minnesota Living with Heart Failure Questionnaire (MLHFQ), a 21-item questionnaire assessing the impact of heart failure on physical, emotional, and social aspects of daily life. Total scores range from 0 (minimum) to 105 (maximum), where higher scores indicate worse quality of life.

    Measured: Baseline and 4 weeks

  3. Functional capacity (6-minute walk test)

    Functional capacity will be assessed using the 6-minute walk test (6MWT) by measuring the distance walked in meters.

    Measured: Baseline and 4 weeks

  4. Heart Rate

    Resting heart rate will be measured in beats per minute (bpm) using a pulse oximeter

    Measured: Baseline and 4 weeks

  5. Hand Grip Strength

    Hand grip strength will be measured using a hand grip dynamometer to assess peripheral muscle strength.

    Measured: Baseline and 4 weeks

  6. Maximum Expiratory Pressure

    Expiratory muscle strength will be assessed by measuring maximum expiratory pressure (MEP) using a maximum expiratory pressure meter.

    Measured: Baseline and 4 weeks

  7. Length of Hospital Stay

    Length of hospital stay will be measured as the number of days from hospital admission to hospital discharge.

    Measured: During the hospitalization period (Up to 7 days)

  8. Estimated peak oxygen uptake (VO₂max)

    Estimated VO₂max (mL/kg/min) calculated from the Duke Activity Status Index (DASI) using a validated published equation

    Measured: Baseline and 4 weeks

  9. Oxygen Saturation (SpO₂)

    Peripheral oxygen saturation (SpO₂) will be measured as a percentage (%) at rest using a pulse oximeter

    Measured: Baseline and 4 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Apr 2026
  2. Study start1 Apr 2026
  3. Primary completion15 Aug 2026 (estimated)
  4. Study completion1 Sep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
135 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07506499
Sponsor's protocol ID
CR-HF-BSU
Status last verified
Apr 2026
First submitted
5 Mar 2026
Last updated
6 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Inspiratory Muscle Trainer, Functional Electrical Stimulation and Standard medical treatment in people with Decompensated Heart Failure, run by Beni-Suef University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 6 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Salma mostafa Elsalhy, BSc (+20 1022792745, salmaabdelfattah@pt.bsu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Maximum Inspiratory Pressure (time frame: Baseline and 4 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in